Indianapolis-based Eli Lilly & Co. (NYSE: LLY) is teaming up with the National Cancer Institute. The company says the partnership is part of the Cancer Moonshot Initiative, which seeks to improve research and expedite the delivery of medicines to cancer patients.
Lilly says it will contribute cancer research data to the institute’s Blood Profiling Atlas, which is an open-access liquid biopsy database that aims to "reduce the development time of effective and safe blood profiling diagnostic technologies."
"Liquid biopsies are going to be critical in the future to both identify specific patients for targeted therapies and to follow their treatment to better determine response to therapy," said Andrew Schade, a distinguished medical fellow in Lilly’s clinical diagnostics laboratory. "We hope knowledge gained from our research efforts in this area will help to accelerate the development of safe and effective blood profiling diagnostic technologies that help people with cancer."
Jan Lundberg, executive vice president of science and technology and president of Lilly Research Laboratories, says external partnerships like this are crucial to discovering and developing new cancer treatments. You can learn more about the Cancer Moonshot Initiative by clicking here.